Subscribe
shutterstock_1960556293_molly_woodward
Molly Woodward / Shutterstock.com
2 September 2021AmericasMuireann Bolger

Pfizer wins patent dispute over Abboject epinephrine shot

Belcher’s chief science officer deceived the US Patent and Trademark Office (USPTO) in order to obtain a patent, the US Court of Appeals for the Federal Circuit has ruled in a win for Pfizer’s subsidiary, Hospira.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSD sues Pfizer’s Wyeth over vaccine patents
14 January 2021   Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
MSD sues Pfizer’s Wyeth over vaccine patents
14 January 2021   Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

More on this story

Americas
MSD sues Pfizer’s Wyeth over vaccine patents
14 January 2021   Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent